נפח מכירות עתידי של החברה: TransCode (RNAZ)

TransCode Therapeutics specializes in developing DNA-based cancer therapies. The company's sales expectations demonstrate market potential, where the value of 0.00 indicates the current magnitude. The firm relies on high-precision RNA platforms, automates genetic analysis using robotics, and efficiently delegates clinical trials to external contractors to reduce internal costs.

The calculation formula for this indicator is based on the correlation between operating cash flows and projected revenues. This metric determines the market value of the asset by assessing its resilience to volatility and the risk of deep drawdowns. For TransCode Therapeutics (RNAZ), such calculations are critical due to sanction barriers regarding the exchange of genetic data. Geopolitical restrictions on reagents directly compress the potential of future contracts. By analyzing the trend of the firm's sales performance, an investor can discern the business's actual margin of safety.